OP \$40.00 3078598

TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1 ETAS ID: TM479240

Stylesheet Version v1.2

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	SECURITY INTEREST

CONVEYING PARTY DATA

Name	Formerly	Execution Date	Entity Type
VIVOPHARM PTY LTD		06/21/2018	Company incorporated under the laws of Australia: AUSTRALIA

RECEIVING PARTY DATA

Name:	SILICON VALLEY BANK	
Street Address:	275 Grove Street	
Internal Address:	Suite 2-200	
City:	Newton	
State/Country:	MASSACHUSETTS	
Postal Code:	02466	
Entity Type:	Corporation: CALIFORNIA	

PROPERTY NUMBERS Total: 1

Property Type	Number	Word Mark
Registration Number:	3078598	VIVOPHARM

CORRESPONDENCE DATA

Fax Number: 8004947512

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent

using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Phone: 202-370-4750

Email: ipteam@cogencyglobal.com

Correspondent Name: Joanna McCall

Address Line 1: 1025 Vermont Ave NW, Suite 1130

Address Line 2: COGENCY GLOBAL INC. Address Line 4: Washington, D.C. 20005

ATTORNEY DOCKET NUMBER:	F177755
NAME OF SUBMITTER:	Laura A. Kenerson
SIGNATURE:	/Laura A. Kenerson/
DATE SIGNED:	06/25/2018

Total Attachments: 10

source=USPTO Submission - IP Security Agreement - Cancer Genetics Inc. (Trademarks)#page2.tif

source=USPTO Submission - IP Security Agreement - Cancer Genetics Inc. (Trademarks)#page3.tif source=USPTO Submission - IP Security Agreement - Cancer Genetics Inc. (Trademarks)#page4.tif source=USPTO Submission - IP Security Agreement - Cancer Genetics Inc. (Trademarks)#page5.tif source=USPTO Submission - IP Security Agreement - Cancer Genetics Inc. (Trademarks)#page7.tif source=USPTO Submission - IP Security Agreement - Cancer Genetics Inc. (Trademarks)#page8.tif source=USPTO Submission - IP Security Agreement - Cancer Genetics Inc. (Trademarks)#page9.tif source=USPTO Submission - IP Security Agreement - Cancer Genetics Inc. (Trademarks)#page10.tif source=USPTO Submission - IP Security Agreement - Cancer Genetics Inc. (Trademarks)#page10.tif source=USPTO Submission - IP Security Agreement - Cancer Genetics Inc. (Trademarks)#page11.tif

INTELLECTUAL PROPERTY SECURITY AGREEMENT

This Intellectual Property Security Agreement (this "Agreement") is entered into as of June 21, 2018, by and between SILICON VALLEY BANK, a California corporation, with a loan production office located at 275 Grove Street, Suite 2-200, Newton, Massachusetts 02466 ("Bank") and VIVOPHARM PTY LTD, a company incorporated under the laws of Australia with its principal place of business located at 240 Plenty Road, Level 3, Suite S29, Bundoora, VIC3083 ("Grantor").

RECITALS

- A. Bank has agreed to make certain advances of money and to extend certain financial accommodations (the "Loans") to Borrower (as defined below) in the amounts and manner set forth in that certain Amended and Restated Loan and Security Agreement by and among Bank, Gentris, LLC ("Gentris"), and Cancer Genetics, Inc. ("Cancer Genetics") dated as of March 22, 2017, as amended by that certain Waiver and First Amendment to Amended and Restated Loan and Security Agreement by and among Bank, Cancer Genetics, and Gentris dated as of May 14, 2018, and as further amended by that certain Joinder and Second Amendment to Amended and Restated Loan and Security Agreement by and among Bank, RDDT a vivoPharm Company Pty Ltd ("RDDT"), Cancer Genetics, Gentris, and vivoPharm, LLC ("Vivo", and collectively with Cancer Genetics, Gentris, and RDDT, the "Borrower") dated as of the date hereof (as the same may be further amended, modified or supplemented from time to time, the "Loan Agreement"; capitalized terms used herein are used as defined in the Loan Agreement).
- B. Grantor has entered into that certain Guarantee dated as of the date hereof, pursuant to which Grantor guarantees the obligations of Borrower under the Loan Agreement. Grantor has also entered into that certain General Security Deed dated as of the date hereof (as the same may be amended, modified or supplemented from time to time, the "Australian Mortgage Debenture").
- C. Bank is willing to make the Loans to Borrower, but only upon the condition, among others, that Grantor shall grant to Bank a security interest in its Copyrights, Trademarks, Patents, and Mask Works (as each term is described below) to secure the obligations of Grantor to Bank.
- D. Pursuant to the terms of the Loan Agreement and the Australian Mortgage Debenture, Grantor has granted to Bank a security interest in all of Grantor's right, title and interest, whether presently existing or hereafter acquired, in, to and under all of the Collateral.

NOW, THEREFORE, for good and valuable consideration, receipt of which is hereby acknowledged, and intending to be legally bound, as collateral security for the prompt and complete payment when due of Grantor's obligations to Bank, Grantor hereby represents, warrants, covenants and agrees as follows:

AGREEMENT

- 1. <u>Grant of Security Interest</u>. To secure Grantor's obligations to Bank, Grantor grants and pledges to Bank a security interest in all of Grantor's right, title and interest in, to and under its intellectual property (all of which shall collectively be called the "Intellectual Property Collateral"), including, without limitation, the following:
- (a) Any and all copyright rights, copyright applications, copyright registrations and like protections in each work of authorship and derivative work thereof, whether published or unpublished and whether or not the same also constitutes a trade secret, now or hereafter existing, created, acquired or held, including without limitation those set forth on Exhibit A attached hereto (collectively, the "Copyrights");
- (b) Any and all trade secrets, and any and all intellectual property rights in computer software and computer software products now or hereafter existing, created, acquired or held:
- (c) Any and all design rights that may be available to Grantor now or hereafter existing, created, acquired or held;
- (d) All patents, patent applications and like protections including, without limitation, improvements, divisions, continuations, renewals, reissues, extensions and continuations-in-part of the same, including without limitation the patents and patent applications set forth on Exhibit B attached hereto (collectively, the "Patents");
- (e) Any trademark and servicemark rights, whether registered or not, applications to register and registrations of the same and like protections, and the entire goodwill of the business of Grantor connected with and symbolized by such trademarks, including without limitation those set forth on Exhibit C attached hereto (collectively, the "**Trademarks**");
- (f) All mask works or similar rights available for the protection of semiconductor chips, now owned or hereafter acquired, including, without limitation those set forth on Exhibit D attached hereto (collectively, the "Mask Works");
- (g) Any and all claims for damages by way of past, present and future infringements of any of the rights included above, with the right, but not the obligation, to sue for and collect such damages for said use or infringement of the intellectual property rights identified above:
- (h) All licenses or other rights to use any of the Copyrights, Patents, Trademarks, or Mask Works and all license fees and royalties arising from such use to the extent permitted by such license or rights;
- (i) All amendments, extensions, renewals and extensions of any of the Copyrights, Trademarks, Patents, or Mask Works; and
- (j) All proceeds and products of the foregoing, including without limitation all payments under insurance or any indemnity or warranty payable in respect of any of the foregoing.

- 2. <u>Recordation</u>. Grantor authorizes the Commissioner for Patents, the Commissioner for Trademarks and the Register of Copyrights and any other government officials to record and register this Agreement upon request by Bank.
- 3. <u>Loan Documents</u>. This Agreement has been entered into pursuant to and in conjunction with the Loan Agreement, which is hereby incorporated by reference. The provisions of the Loan Agreement shall supersede and control over any conflicting or inconsistent provision herein. The rights and remedies of Bank with respect to the Intellectual Property Collateral are as provided by the Loan Agreement and related documents, and nothing in this Agreement shall be deemed to limit such rights and remedies.
- 4. <u>Execution in Counterparts</u>. This Agreement may be executed in counterparts (and by different parties hereto in different counterparts), each of which shall constitute an original, but all of which when taken together shall constitute a single contract. Delivery of an executed counterpart of a signature page to this Agreement by facsimile or in electronic (i.e., "pdf" or "tif" format) shall be effective as delivery of a manually executed counterpart of this Agreement.
- 5. <u>Successors and Assigns</u>. This Agreement will be binding on and shall inure to the benefit of the parties hereto and their respective successors and assigns.
- 6. <u>Governing Law</u>. This Agreement and any claim, controversy, dispute or cause of action (whether in contract or tort or otherwise) based upon, arising out of or relating to this Agreement and the transactions contemplated hereby and thereby shall be governed by, and construed in accordance with, the laws of the United States and the State of New York without giving effect to any choice or conflict of law provision or rule (whether of the State of New York or any other jurisdiction).

[Signature page follows.]

	arties have caused this Intellectual Property Security icers thereunto duly authorized as of the first date
GRANTOR:	
Executed by VIVOPHARM PTY LTD is accordance with Section 127 of the Corporations Act 2001	n
Jehn Hopey S	
Signature of director	Signature of director/company secretary (Please delete as applicable)
John A. Roberts	Ralf Brandt
Name of director (print)	Name of director/company secretary (print)
BANK:	
SILICON VALLEY BANK	

By:_____

Title:____

Agreement to be duly executed by its officers thereunto duly authorized as of the first date written above.

GRANTOR:

Executed by VIVOPHARM PTY LTD in accordance with Section 127 of the Corporations Act 2001

Signature of director (Please delete as applicable)

John A. Roberts

Name of director (print)

Ralf Brandt

Name of director/company secretary (print)

SILICON VALLEY BANK

Title:

IN WITNESS WHEREOF, the parties have caused this Intellectual Property Security

TRADEMARK

REEL: 006363 FRAME: 0088

Agreement to be duly executed by its officers written above.	thereunto duly authorized as of the first date
GRANTOR:	
Executed by VIVOPHARM PTY LTD in accordance with Section 127 of the Corporations Act 2001	
Signature of director	Signature of director/company secretary (Please delete as applicable)
Name of director (print)	Name of director/company secretary (print)
BANK:	
SILICON VALLEY BANK By: Mah	

Title: Vice President

EXHIBIT A

Copyrights

None.

EXHIBIT B

Patents

None.

EXHIBIT C

Trademarks

Description

Registration/ Application Number Registration/ Application Date

vivopharm label

980818 - Australia

vivo Pharm

VIVOPHARM logo

1519958 - Australia

VIVOPHARM

VIVOPHARM logo

1169684 - Madrid Protocol (TM)



VIVOPHARM logo

1169684 - European Community



VIVOPHARM & oval device in colour

4586443 - USA

August 19, 2014



vivoPHARM Stylised

3078598 - USA

April 11, 2006

VIVOPHARM

EXHIBIT D

Mask Works

None.

TRADEMARK
REEL: 006363 FRAME: 0093

RECORDED: 06/25/2018